| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000022826 |
| Receipt No. | R000026259 |
| Official scientific title of the study | Supplemental effect of fermented soy product on rush oral immunotherapy (F-SOI)- Double blind - randomized placebo control trial - |
| Date of disclosure of the study information | 2016/06/21 |
| Last modified on | 2018/06/29 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Supplemental effect of fermented soy product on rush oral immunotherapy (F-SOI)- Double blind - randomized placebo control trial - | |
| Title of the study (Brief title) | F-SOI | |
| Region |
|
|
| Condition | ||||
| Condition | food allergy | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | To evaluate the efficacy of combined therapy comprising fermanted soy product with rush oral immunotherapy. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The total score of allergic reaction score plus rescue drug score during rash phase of OIT. |
| Key secondary outcomes | The amount of food consumption and the proportion of patients who reached the target dose (20g of boiled egg, 100ml of milk and 100g of udon noodle) at discharge and at 3 months after discharge.
The changes in value of laboratory data (e.g. specific IgE titer) The changes in value of the threshold dose of antigen and severity of allergic reaction provoked in OFCs |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | YES |
| Concealment | Numbered container method |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | the consumption of 600mg/day fermanted soy product from 1~2 month before ROIT to 3 months after the end of rash phase of OIT | |
| Interventions/Control_2 | the consumption of plasebo from 1~2 month before starting ROIT until 3 month after the end of rash phase of OIT | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | patient with severe food allergy for egg, milk, wheat diagnosed by oral food challenge | |||
| Key exclusion criteria | patients with severe comorbidity
patients with uncontrollable asthma or atopic dermatitis patients with severe food allergy for soybeans patients whom the doctor assess ineligible |
|||
| Target sample size | 55 | |||
| Research contact person | |
| Name of lead principal investigator | Komei Ito |
| Organization | Aichi Children's Health and Medical Center |
| Division name | Department of Allergy |
| Address | 7-426, Morioka, Obu, Aichi 474-8710, Japan |
| TEL | 0562-43-0500 |
| koumei_itoh@mx.achmc.pref.aichi.jp | |
| Public contact | |
| Name of contact person | Iwao Tajima |
| Organization | Aichi Children's Health and Medical Center |
| Division name | Department of Allergy |
| Address | 7-426, Morioka, Obu, Aichi 474-8710, Japan |
| TEL | 0562-43-0500 |
| Homepage URL | |
| iwao_tajima@sk00106.achmc.pref.aichi.jp | |
| Sponsor | |
| Institute | Aichi Children's Health and Medical Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | NICHIMO BIOTICS Co.,Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | あいち小児保健医療総合センター(愛知県)
|
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000026259 |